Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects
https://doi.org/10.4081/aiua.2020.4.326
Accepted: September 8, 2020
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Retinitis pigmentosa represents a heterogeneous group of degenerative hereditary pathologies of the retinal photoceptors, some forms mainly affect the cones and others the rods. The prevalence of the disease is of 1 case per 3000-5000 inhabitants, in 80-90% of cases these are forms with prevalent involvement of the rods (RCD) and in 10-20% of cases of forms with prevalent involvement of the cones (CRD) [...].
Pagon RA. Retinitis pigmentosa. Surv Ophthalmol 1988; 33: 137–77. DOI: https://doi.org/10.1016/0039-6257(88)90085-9
Parmeggiani F, Sato G, De Nadai K, Romano MR, Binotto A, Costagliola C. Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date. Curr Genomics 2011; 12: 250–9. DOI: https://doi.org/10.2174/138920211795860125
Boughman JA, Vernon M, Shaver KA. Usher syndrome: definition and estimate of prevalence from two high-risk populations. J Chronic Dis 1983; 36: 595–603. DOI: https://doi.org/10.1016/0021-9681(83)90147-9
Basu A, Ryder REJ. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64: 2667–88. DOI: https://doi.org/10.2165/00003495-200464230-00004
Hakky TS, Jain L. Current use of phosphodiesterase inhibitors in urology. Turkish J Urol 2015; 41: 88–92. DOI: https://doi.org/10.5152/tud.2015.46354
Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39: 1286–95. DOI: https://doi.org/10.1345/aph.1E487
Kuthe A. Phosphodiesterase 5 inhibitors in male sexual dysfunction. Curr Opin Urol 2003; 13: 405–10. DOI: https://doi.org/10.1097/00042307-200309000-00008
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–404. DOI: https://doi.org/10.1056/NEJM199805143382001
Eardley I,Cartledge J.Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002; 56: 300-4.
Limin M, Johnsen N, Hellstrom WJG. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010; 19: 1427–37. DOI: https://doi.org/10.1517/13543784.2010.518955
Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011; 5: 435–43.
Wang R, Burnett AL, Heller WH, Omori K, Kotera J, Kikkawa K. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9: 2122–9. DOI: https://doi.org/10.1111/j.1743-6109.2012.02822.x
Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763–71.
Carson CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 96: 37M-41M DOI: https://doi.org/10.1016/j.amjcard.2005.07.010
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
